WO2002044150A1 - Chemical process and new intermediates - Google Patents

Chemical process and new intermediates Download PDF

Info

Publication number
WO2002044150A1
WO2002044150A1 PCT/HU2001/000121 HU0100121W WO0244150A1 WO 2002044150 A1 WO2002044150 A1 WO 2002044150A1 HU 0100121 W HU0100121 W HU 0100121W WO 0244150 A1 WO0244150 A1 WO 0244150A1
Authority
WO
WIPO (PCT)
Prior art keywords
stands
group
general formula
hydrogen
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HU2001/000121
Other languages
French (fr)
Inventor
Sándor BOKOTEY
Gézáné GALAMBOS
Félix HAJDÚ
István HERMECZ
ágnes Horváth
Józsefné IVANICS
Gyuláné KISS
Lajos Nagy
Benjámin PODÁNYI
Attila Simon
Judit Sipos
Ágota SMELKÓNÉ ESEK
Anna Szabó
Árpádné VASVÁRI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Priority to MXPA03004426A priority Critical patent/MXPA03004426A/en
Priority to EP01998539A priority patent/EP1345897A1/en
Priority to US10/432,494 priority patent/US20040198793A1/en
Priority to PL01363702A priority patent/PL363702A1/en
Priority to BR0115501-6A priority patent/BR0115501A/en
Priority to CA002430064A priority patent/CA2430064A1/en
Priority to AU2002220932A priority patent/AU2002220932A1/en
Priority to HU0303062A priority patent/HUP0303062A2/en
Priority to JP2002546520A priority patent/JP2004518641A/en
Publication of WO2002044150A1 publication Critical patent/WO2002044150A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/63—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the subject of the invention is a new process for the preparation of a compound of the general formula (I) and pharmaceutically acceptable salts and solvates thereof
  • R 1 stands for hydrogen or methyl group
  • R 2 , R 3 , R 4 , R 5 stand independently from each other for hydrogen, methyl, ethyl, hydroxyl, acetyloxy, methoxy, ethoxy, methyltio, trifluoromethyl or amino group or halogen atom,
  • R stands for hydrogen, a -(CH 2 ) n R 6 group or a group of the general formula a.), wherein
  • R 6 stands for carboxyl or a -COOR 7 group
  • R 7 stands for a C 1- alkyl group
  • n 1, 2, 3, 4 or 5
  • m zero or 1
  • R 8 stands for a substituted phenyl group of the general formula b.), wherein R 10 stands for hydrogen or methoxy group,
  • R 11 stands for hydrogen, methyl, ethyl, isopropyl, methoxy or ethoxy group or halogen atom
  • R stands for hydrogen, methyl, ethyl or methoxy group or halogen atom, or
  • R and R form together a methylenedioxy group
  • R 9 stands for a -CH 2 -R 13 , -(CH 2 ) 2 -R 13 , -S-CH 2 -R 13 , -CH 2 -S-R 13 or C 5 . 8 alkyl group, wherein
  • R 13 stands for C 5 . 7 cycloalkyl group, with the proviso that R 10 , R 11 and R 12 can not stand at the same time for hydrogen.
  • the compounds of the general formula (I) are cholecystokinin A (CCK-A) agonists, which are useful in the treatment of the disorders of the a gastrointestinal tract and of the central nervous system.
  • CCK-A cholecystokinin A
  • the compounds of the general formula (I) are prepared by reacting the 2-aminothiazole derivatives of the general formula (IV), wherein the meaning of R 8 and R 9 is the same as defined above, with the acids of the general formula (V), wherein the meaning of R 1 , R 2 , R 3 , R 4 and R 5 is the same as above.
  • the subject of our invention is a new process for the preparation of a compound of the general formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the meanings of R, R 1 , R 2 , R 3 , R 4 , R 5 , R 8 and R 9 are as defined above, characterised by reacting an N-(amino-thioxo-methyl)-lH-indole-2- carboxamide of the general formula (II), wherein R 1 , R 2 , R 3 , R 4 , R 5 and R are as defined above, with an ⁇ -halogen-ketone of the general formula (III), wherein X stands for halogen atom, R 8 and R 9 are as defined above, and transforming the compound of the general formula (I) or its solvate thus obtained into its salt or liberating it from its salt.
  • Reaction of the compounds of the general formula (II) and (III) is preferably performed in the presence of a solvent, at a temperature between room temperature and 120°C , preferably at a temperature between 80°C and 120°C.
  • a dipolar aprotic solvent as for instance N,N-dimethylformamide or N-methyl-2-pyrrolidone
  • the resulting compound of the general formula (I) precipitates from the reaction mixture on adding it to a protic solvent, favourably to water or alcohol, or to the mixture of the two, or by the addition of ethanolamine and ethanol to the reaction mixture.
  • the product can be isolated from the reaction mixture by filtration.
  • the starting N-(aminothioxomethyl)-lH-indole-2-carboxamides of the general formula (II), wherein R , R , R , R , R and R are the same as defined above, are new compounds.
  • the invention also relates to the new compounds of the general formula (II), wherein R 1 , R 2 , R 3 , R , R 5 and R are the same as defined above, and to the process for the preparation thereof.
  • N-(aminothioxomethyl)-lH-indole-2-carboxamides of the general formula (II) of the present invention can be prepared by transforming an lH-indole- 2-carboxylic acid of the general formula (V), wherein R 1 , R 2 , R 3 , R , R 5 and R are the same as defined above, into an lH-indole-2-carboxylic acid halogenide of the general formula (VI), wherein R , R , R , R , R and R are the same as defined above and the meaning of Hlg is halogen, reacting the resulting compound of the general formula (VI) with potassium thiocyanate, and reacting the thus obtained isothiocyanate of the general formula (VIII), wherein R 1 , R 2 , R 3 , R 4 , R 5 and R are the same as defined above, with ammonia or ammonium hydroxide.
  • the acid halogenides of the general formula (VI), preferably the acid chlorides, can be obtained from the appropriate acids by methods known from the literature, in the case of an acid chloride for instance, favourably by refluxing with thionyl chloride, without solvent, or in the presence of an aprotic solvent.
  • Acylation of the potassium thiocyanate with the acid halogenide of the general formula (VI) on the effect of reflux in a dipolar-aprotic solvent, preferably in acetone or methyl ethyl ketone takes place at the sulphur atom and results the thiocyanate derivative of the general formula (VII), which by a fast thermic rearrangement transforms into the isothiocyanate of the general formula (VIII).
  • This compound is rather unstable, therefore it is taken into the next reaction step without isolation.
  • the starting ⁇ -halogen-ketone derivatives of the general formula (III), wherein X stands for halogen atom, preferably bromo atom, R 8 and R 9 are the same as defined above, can be prepared by halogenation of the appropriate ketone derivative of the general formula (IX), wherein R 8 and R 9 are the same as defined above, by using methods known from the literature, preferably by reacting it with bromine, in dichloromethane.
  • the ketone derivative of the general formula (IX), wherein R 8 and R 9 are the same as defined above, can be obtained by methods known from the litarature, by Friedel-Crafts acylation of the appropriately substituted methoxybenzene with the appropriate acid chloride, in the presence of Lewis acids, e.g. TiCl , A1C1 or FeCl 3 , in aprotic solvents, favourably in dichloromethane (publication WO 99/15525).
  • Lewis acids e.g. TiCl , A1C1 or FeCl 3
  • R means an alkyl group -CH 2 .R , (CH 2 ) 2 -R , or
  • (C 5 . 8 ) can be prepared from the appropriate acids available on the market, by general methods known in the literature, as for instance by reaction with thionyl chloride, oxalyl chloride or with POCl 3 / DMF .
  • Our invention relates furthermore to the new compounds of the general formula (III) wherein R 9 stands for cycloalkylmethylthio- or cyckloalkylthiomethyl- group and the meaning of R is the same as defined above, and the process for the preparation thereof.
  • the new compounds of the general formula (III), wherein R 9 stands for cycloalkylmethylthio- or cyckloalkylthiomethyl- group and the meaning of R 8 is the same as defined above can be prepared by acylation of a methoxybenzene of the general formula (X), wherein the meaning of R 10 , R 1 and R 12 is the same as defined above, with an acid chloride of the general formula (XI), wherein R 14 stands for (C 5 .
  • cycloalkyl-group o means 1 or 2 and p means zero or 1, in the presence of an aprotic solvent, preferably dichloromethane, and a Lewis acid, preferably titane tetrachloride or aluminium chloride, at 0-5°C, followed by halogenation in an aprotic solvent by methods used in the literature, favourably by bromination in dichloromethane with bromine.
  • an aprotic solvent preferably dichloromethane
  • a Lewis acid preferably titane tetrachloride or aluminium chloride
  • the acid chloride of the general formula (XI), wherein the meaning of R 14 , o and p is the same as defined above, can be obtained from an acid of the general formula (XII), wherein the meaning of R 14 , o and p is the same as defined above, by reaction with thionyl chloride or oxalyl chloride in an aprotic solvent, preferably in dichloromethane .
  • the dark solution is heated under reflux for an additional hour, then it is evaporated in vacuum and 150 ml of toluene is distilled through the residue.
  • the solid residue is dissolved in 500 ml of methyl ethyl ketone at 40-50 °C and added in about 20 minutes to the stirred refluxing suspension of 29.15 g (0.30 mol) of potassium thiocyanate and 150 ml of methyl ethyl ketone.
  • the mixture is refluxed for an additional 30 minutes, then it is cooled to +5 °C. Under stirring and external cooling ammonia gas is introduced into the mixture, while its temperature elevates to 34 °C and the product precipitates from the solution in the form of yellow crystals.
  • a suspension made of 0.85 g (8.4 mmol) of potassium thiocyanate and 5 ml of acetone is heated to 50 °C and to it the acid chloride dissolved in 50 ml of acetone is dropped.
  • the reaction mixture is boiled for 30 minutes, then it is cooled from ice-water bath to 6-8 °C and ammonia gas is introduced until the temperature of the reaction mixture is increasing.
  • the mixture is then stirred on ice- water bath for 1 hour, 25 ml of water is added to it, and stirring is continued for another hour.
  • the crystals are filtered off in vacuum, washed with water-acetone 1 : 1 mixture to obtain 1.75 g of the title compound in the form of beige-coloured crystals, mp: 210- 212 °C.
  • the acid chloride is refluxed in 10 ml of acetone with 0.44 g (4.5 mmol) of potassium thiocyanate for 30 minutes, then the mixture is cooled from ice-water bath to 0-5°C and 1 ml of 25% ammonium hydroxide is added to it.
  • the thick suspension is diluted with 5 ml of acetone, stirred at room temperature for 30 minutes.
  • the crystals are filtered off in vacuum, washed subsequently with water and acetone to obtain 1.16 g of yellowish- drab crystals of the title compound, mp: 202-206 °C.
  • the acid chloride is refluxed in 10 ml of acetone with 1.05 g (10.7 mmol) of potassium thiocyanate for 30 minutes, then the mixture is cooled from ice-water bath to 0-5°C and 2 ml of 25% ammonium hydroxide is added to it.
  • the thick suspension is diluted with 10 ml of acetone and 10 ml of acetonitrile, stirred at room temperature for 30 minutes, then under stirring 90 ml of water is added to the suspension and stirring is continued for another 30 minutes.
  • the crystals are filtered off in vacuum, washed with water to obtain 3.17 g of butter-coloured crystals of the title compound, mp: 222-224 °C.
  • the acid chloride is refluxed in 15 ml of acetone with 0.56 g (5.7 mmol) of potassium thiocyanate for 1 hour, then the mixture is cooled from ice-water bath to 0-5°C and 1.25 ml of 25% ammonium hydroxide is added to it.
  • the suspension is stirred at room temperature for 30 minutes, diluted with 15 ml of water and stirred for another 30 minutes.
  • the crystals are filtered off in vacuum, washed with water to obtain 1.16 g of yellow crystals of the title compound, mp: 160-162 °C.
  • Example 11 The proccess described in Example 11. is followed, starting from 1,4- dimethoxybenzene instead of 1,3-dimethoxybenzene.
  • the product obtained by evaporation is an oil, weight: 9.8 g.
  • the phases are separated, the aqueous phase is extracted with 30 ml of dichloromethane, the united organic phase is stirred for 30 minutes with 40 ml of IN sodium hidroxide solution, the organic phase is washed with 40 ml of saturated sodium chloride solution, dried and evaporated. The residue is taken up in 20 ml of methanol. The resulting crystals are filtered off in vacuum, to obtain 5.33 g white crystals of the title compound, mp: 51-53 °C.
  • reaction mixture is extracted twice with 200 ml of ethyl acetate.
  • organic layer is washed with 200 ml of water, dried over anhydrous sodium sulfate and evaporated.
  • the residual 16.5 g of crude product is purified by chromatography using 10: 1 toluene-methanol mixture as eluent. Collecting and evaporating the pure fractions the title compound was obtained in the form of a pale oil, which was used for the next step without further purification.
  • the butter- coloured suspension is stirred at room temperature for 30 minutes, the crystals are filtered off in vacuum, crystallized from N,N-dimethylformamide - water mixture. 2.82 g pale beige-coloured crystals are obtained as crude product, mp: 154-162 °C.
  • Example 25 The crude product is purified by chomatography using toluene- methanol 10:1 mixture eluent to obtain the title compound as white crystals, mp: 203-205 °C.
  • Example 38 white crystals of the title compound are obtained, mp: 150-152°C.
  • Example 38 white crystals of the title compound are obtained, mp: 163-165°C.
  • Fig. 1 shows the general formula (I)
  • Fig. 2 shows the general formula (II)
  • Fig. 3 shows the general formula (III)
  • Fig. 4 shows the general formula (IV)
  • Fig. 5 shows the general formula (V)
  • Fig. 6 shows the general formula (VI)
  • Fig. 7 shows the general formula (VII)
  • Fig. 8 shows the general formula (VIII)
  • Fig. 9 shows the general formula (IX)
  • Fig. 10 shows the general formula (X)
  • Fig. 11 shows the general formula (XI)
  • Fig. 12 shows the general formula (XII)
  • Fig. 13 shows the general formula (XIII)
  • Fig. 14 shows the general formula (XIV)
  • Fig. 15 shows the general formula (XV)
  • Fig. 16 shows the general formula (XVI).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Process for the preparation of a compound of the general formula (I) and pharmaceutically acceptable salts and solvates thereof, (I) characterised by reacting an N-(amino-tioxo-methyl)-1H-indole-2-carboxamide of the general formula (II), with an α-halogen-ketone of the general formula (III), wherein X stands for halogen.

Description

Chemical process and new intermediates
The subject of the invention is a new process for the preparation of a compound of the general formula (I) and pharmaceutically acceptable salts and solvates thereof
- wherein
R1 stands for hydrogen or methyl group,
R2, R3, R4, R5 stand independently from each other for hydrogen, methyl, ethyl, hydroxyl, acetyloxy, methoxy, ethoxy, methyltio, trifluoromethyl or amino group or halogen atom,
R stands for hydrogen, a -(CH2)nR6 group or a group of the general formula a.), wherein
R6 stands for carboxyl or a -COOR7 group, R7 stands for a C1- alkyl group, n= 1, 2, 3, 4 or 5, m= zero or 1,
R8 stands for a substituted phenyl group of the general formula b.), wherein R10 stands for hydrogen or methoxy group,
R11 stands for hydrogen, methyl, ethyl, isopropyl, methoxy or ethoxy group or halogen atom,
11
R stands for hydrogen, methyl, ethyl or methoxy group or halogen atom, or
1 1 1
R and R form together a methylenedioxy group, R9 stands for a -CH2-R13, -(CH2)2-R13, -S-CH2-R13, -CH2-S-R13 or C5.8 alkyl group, wherein
R13 stands for C5.7 cycloalkyl group, with the proviso that R10, R11 and R12 can not stand at the same time for hydrogen. The compounds of the general formula (I) are cholecystokinin A (CCK-A) agonists, which are useful in the treatment of the disorders of the a gastrointestinal tract and of the central nervous system.
Preparation of the compounds of the general formula (I) is described in the publication WO 99/15525. According to the process given in the publication, the compounds of the general formula (I) are prepared by reacting the 2-aminothiazole derivatives of the general formula (IV), wherein the meaning of R8 and R9 is the same as defined above, with the acids of the general formula (V), wherein the meaning of R1, R2, R3, R4 and R5 is the same as above. The subject of our invention is a new process for the preparation of a compound of the general formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the meanings of R, R1, R2, R3, R4, R5, R8 and R9 are as defined above, characterised by reacting an N-(amino-thioxo-methyl)-lH-indole-2- carboxamide of the general formula (II), wherein R1, R2 , R3, R4 , R5 and R are as defined above, with an α-halogen-ketone of the general formula (III), wherein X stands for halogen atom, R8 and R9 are as defined above, and transforming the compound of the general formula (I) or its solvate thus obtained into its salt or liberating it from its salt.
Reaction of the compounds of the general formula (II) and (III) is preferably performed in the presence of a solvent, at a temperature between room temperature and 120°C , preferably at a temperature between 80°C and 120°C.
As for solvent, preferably a dipolar aprotic solvent, as for instance N,N-dimethylformamide or N-methyl-2-pyrrolidone can be applied. The resulting compound of the general formula (I) precipitates from the reaction mixture on adding it to a protic solvent, favourably to water or alcohol, or to the mixture of the two, or by the addition of ethanolamine and ethanol to the reaction mixture. The product can be isolated from the reaction mixture by filtration. The starting N-(aminothioxomethyl)-lH-indole-2-carboxamides of the general formula (II), wherein R , R , R , R , R and R are the same as defined above, are new compounds.
In accordance with the above, the invention also relates to the new compounds of the general formula (II), wherein R1, R2, R3, R , R5 and R are the same as defined above, and to the process for the preparation thereof.
The N-(aminothioxomethyl)-lH-indole-2-carboxamides of the general formula (II) of the present invention can be prepared by transforming an lH-indole- 2-carboxylic acid of the general formula (V), wherein R1, R2, R3, R , R5 and R are the same as defined above, into an lH-indole-2-carboxylic acid halogenide of the general formula (VI), wherein R , R , R , R , R and R are the same as defined above and the meaning of Hlg is halogen, reacting the resulting compound of the general formula (VI) with potassium thiocyanate, and reacting the thus obtained isothiocyanate of the general formula (VIII), wherein R1, R2, R3, R4, R5 and R are the same as defined above, with ammonia or ammonium hydroxide.
The acid halogenides of the general formula (VI), preferably the acid chlorides, can be obtained from the appropriate acids by methods known from the literature, in the case of an acid chloride for instance, favourably by refluxing with thionyl chloride, without solvent, or in the presence of an aprotic solvent. Acylation of the potassium thiocyanate with the acid halogenide of the general formula (VI) on the effect of reflux in a dipolar-aprotic solvent, preferably in acetone or methyl ethyl ketone, takes place at the sulphur atom and results the thiocyanate derivative of the general formula (VII), which by a fast thermic rearrangement transforms into the isothiocyanate of the general formula (VIII). This compound is rather unstable, therefore it is taken into the next reaction step without isolation.
Addition of the ammonia is effected at 0-30°Cs by saturation of the reaction mixture with ammonia gas or with ammonium hydroxide. The product can be isolated from the reaction mixture by filtration. The compounds of formula (V), wherein R, R1, R2, R3, R4 and R5 are the same as defined above can be purchased, or prepared as described in the publication WO 99/15525.
The starting α-halogen-ketone derivatives of the general formula (III), wherein X stands for halogen atom, preferably bromo atom, R8 and R9 are the same as defined above, can be prepared by halogenation of the appropriate ketone derivative of the general formula (IX), wherein R8 and R9 are the same as defined above, by using methods known from the literature, preferably by reacting it with bromine, in dichloromethane. The ketone derivative of the general formula (IX), wherein R8 and R9 are the same as defined above, can be obtained by methods known from the litarature, by Friedel-Crafts acylation of the appropriately substituted methoxybenzene with the appropriate acid chloride, in the presence of Lewis acids, e.g. TiCl , A1C1 or FeCl3, in aprotic solvents, favourably in dichloromethane (publication WO 99/15525).
Q π 1 ^ The acid chlorides where R means an alkyl group -CH2.R , (CH2)2-R , or
(C5.8) can be prepared from the appropriate acids available on the market, by general methods known in the literature, as for instance by reaction with thionyl chloride, oxalyl chloride or with POCl3 / DMF .
Compounds of the general formula (III) wherein R9 stands for cycloalkylmethylthio- or cyckloalkylthiomethyl- group and the meaning of R8 is the same as defined above, are new compounds.
Our invention relates furthermore to the new compounds of the general formula (III) wherein R9 stands for cycloalkylmethylthio- or cyckloalkylthiomethyl- group and the meaning of R is the same as defined above, and the process for the preparation thereof.
According to our invention the new compounds of the general formula (III), wherein R9 stands for cycloalkylmethylthio- or cyckloalkylthiomethyl- group and the meaning of R8 is the same as defined above, can be prepared by acylation of a methoxybenzene of the general formula (X), wherein the meaning of R10, R1 and R12 is the same as defined above, with an acid chloride of the general formula (XI), wherein R14 stands for (C5.7) cycloalkyl-group, o means 1 or 2 and p means zero or 1, in the presence of an aprotic solvent, preferably dichloromethane, and a Lewis acid, preferably titane tetrachloride or aluminium chloride, at 0-5°C, followed by halogenation in an aprotic solvent by methods used in the literature, favourably by bromination in dichloromethane with bromine. The acid chloride of the general formula (XI), wherein the meaning of R14, o and p is the same as defined above, can be obtained from an acid of the general formula (XII), wherein the meaning of R14, o and p is the same as defined above, by reaction with thionyl chloride or oxalyl chloride in an aprotic solvent, preferably in dichloromethane . The acid of the general formula (XII), wherein the meaning of R14, o and p is the same as defined above can be prepared by alkylating an appropriate cycloalkylmethylthio, or cycloalkylthio compound of the general formula (XIII), in alkaline media, with an bromoalkylcarboxylic acid esters of the general formula (XIV), wherein R15 stands for methyl or ethyl group and the meaning of o is the same as defined above, preferably with bromoacetic acid methyl ester (o=l), or with 3-bromopropionic acid ethyl ester (o=2), and by subsequent hydrolysis of the ester group.
The cycloalkylthio compound of the general formula (X3II) can be purchased, or it can be prepared from the appropriate cycloalkylmethyl bromide of the general formula (XV), available on the market, by reacting it in a protic solvent, favourably in ethanol with thiocarbamide and by hydrolysing the resulting S-alkyl- isothiuronium salt of the general formula (XVI), wherein the meaning of R14 is the same as defined above, and p=zero, with an alkali hydroxide solution, preferably sodium hydroxide solution. Further details of the invention are demonstrated by the following examples, without limiting the claims to the examples. EXAMPLES Preparation of compounds of the general formula (II) 1.) Preparation of the N-(aminothioxomethyl)-5,7-dimethyl-l- (methoxycarbonylmethyl)-iH-indole-2-carboxamide The mixture of 78.35 g (0.30 mol) of 5,7-dimethyl-2-(hydroxycarbonyl)-lH- indole-1 -acetic acid methyl ester, 390 ml of dichloromethane and 24.08 ml'(39.26 g = 0.33 mol) of thionyl chloride is heated under reflux conditions and stirring. The solid starting material dissolves in about 45 minutes. The dark solution is heated under reflux for an additional hour, then it is evaporated in vacuum and 150 ml of toluene is distilled through the residue. The solid residue is dissolved in 500 ml of methyl ethyl ketone at 40-50 °C and added in about 20 minutes to the stirred refluxing suspension of 29.15 g (0.30 mol) of potassium thiocyanate and 150 ml of methyl ethyl ketone. The mixture is refluxed for an additional 30 minutes, then it is cooled to +5 °C. Under stirring and external cooling ammonia gas is introduced into the mixture, while its temperature elevates to 34 °C and the product precipitates from the solution in the form of yellow crystals.
When the temperature starts to decrease (after about 10 minutes) the gas inlet is stopped and the reaction mixture is allowed to stand for another hour in a bath of 5-10 °C, then 650 ml of water is added to the mixture under stirring and the resulting two-phase suspension is stirred for 25 minutes. The crystals are filtered off in vacuum, washed subsequently with water and acetone. 87.03 g of pale-yellow crystals of the crude product are obtained, mp: 226-231 °C.
2.) Preparation of N-(aminothioxomethyl)-5-methyl-l-
(methoxycarbonylmethyl)-7H-indole-2-carboxamide The mixture of 4.46 g (18 mmol) of 5-methyl-2-(hydroxycarbonyl)-lH- indole-1 -acetic acid methyl ester, 22 ml of dichloromethane, 1.5 ml (2.4 g=20 mmol) of thionyl chloride and 3 drops of N,N-dimethylformamide is heated under reflux conditions for 2 hours. The thick suspension turns into a yellow solution, which is evaporated in vacuum and 10 ml of toluene is distilled through the residue. The thus obtained acid chloride is dissolved in 50 ml of acetone and dropped to the boiling suspension of 1.75 g (18 mmol) of potassium thiocyanate and 10 ml of acetone. The reaction mixture is boiled for 45 minutes, then it is cooled from ice- water bath to 4-6 °C and ammonia gas is introduced as long as the exothermic reaction lasts. The mixture is then stirred on ice-water bath for 1 hour, 60 ml of water is added to it, and stirring is continued for another hour. The crystals are filtered off in vacuum, washed with water to obtain 4.45 g of the title compound in the form of beige-coloured crystals, mp: 222-224 °C.
3.) Preparation of N-(aminothioxomethyl)-3,5-dimethyl-l-(methoxycarbonyl methyl)-7H-indole-2-carboxamide
The mixture of 2.2 g (8.48 mmol) of 3,5-dimethyl-2-(hydroxycarbonyι)-lH- indole-1 -acetic acid methyl ester, 12 ml of dichloromethane, 1.2 g (11 mmol) ~ 0.75 ml of thionyl chloride and 2 drops of N,N-dimethylformamide is heated under reflux conditions for 1.5 hours, while the thick suspension turns into a yellow solution, then it is evaporated in vacuum and 5 ml of toluene is distilled through the residue. A suspension made of 0.85 g (8.4 mmol) of potassium thiocyanate and 5 ml of acetone is heated to 50 °C and to it the acid chloride dissolved in 50 ml of acetone is dropped. The reaction mixture is boiled for 30 minutes, then it is cooled from ice-water bath to 6-8 °C and ammonia gas is introduced until the temperature of the reaction mixture is increasing. The mixture is then stirred on ice- water bath for 1 hour, 25 ml of water is added to it, and stirring is continued for another hour. The crystals are filtered off in vacuum, washed with water-acetone 1 : 1 mixture to obtain 1.75 g of the title compound in the form of beige-coloured crystals, mp: 210- 212 °C.
4.) Preparation of the mixture of N-(aminothioxomethyl)-4, 5 -dimethyl- 1- (methoxycarbonylmethyl)-/H-indole-2-carboxamide and N-(aminothioxomethyl)- 5,6-dimethyl-l-(methoxycarbonylmethyl)-7H-indole-2-carboxamide
5.23 g (20 mmol) of the mixture of 4,5-dimethyl-2-(hydroxycarbonyι)-lH- indole-1 -acetic acid methyl ester and 5,6-dimethyl-2-(hydroxycarbonyl)-lH-indole- 1 -acetic acid methyl ester is refluxed for 2 hours in 25 ml of dichloromethane, in the presence of 2.6 g (22 mmol) ~ 1.6 ml of thionyl chloride and 3 drops of N,N- dimethylformamide, while the thick suspension turns into a yellow solution, then it is evaporated in vacuum and 10 ml of toluene is distilled through the residue. A suspension made of 1.98 g (20 mmol) of potassium thiocyanate and 10 ml of acetone is heated to 50 °C and the acid chloride dissolved in 40 ml of acetone is dropped to it. The reaction mixture is boiled for 45 minutes, then it is cooled from ice-water bath to 0-5 °C and ammonia gas is introduced until the temperature of the reaction mixture is increasing. The mixture is then stirred on ice-water bath for 1 hour, 60 ml of water is added to it, and stirring is continued for another hour. The crystals are filtered off in vacuum, washed with water-acetone 1:1 mixture to obtain 5.15 g of the title compound in the form of beige-coloured crystals, mp: 214- 216 °C. 5.) Preparation of N-(aminothioxomethyl)-5 -methoxy- l-(methoxycarbonyl methyl)- iH-indole-2-carboxamide
1.2 g (4.5 mmol) of 5-methoxy-2-(hydroxycarbonyl)-lH-indole-l -acetic acid methyl ester and 0.65 g (5 mmol) ~ 0.4 ml of thionyl chloride in 10 ml of dichloromethane, in the presence of 1 drop of N,N-dimethylformamide are heated under reflux conditions for 1 hour. The dark solution is then evaporated in vacuum and 10 ml of toluene is distilled through the residue. The acid chloride is refluxed in 10 ml of acetone with 0.44 g (4.5 mmol) of potassium thiocyanate for 30 minutes, then the mixture is cooled from ice-water bath to 0-5°C and 1 ml of 25% ammonium hydroxide is added to it. The thick suspension is diluted with 5 ml of acetone, stirred at room temperature for 30 minutes. The crystals are filtered off in vacuum, washed subsequently with water and acetone to obtain 1.16 g of yellowish- drab crystals of the title compound, mp: 202-206 °C.
6.) Preparation of N-(aminothioxomethyl)-5,7-dimethyl-7H-indole-2- carboxamide 4.73 g (0.025 mol) of 5,7-dimethyl-lH-indole-2-carboxylic acid are suspended in 40 ml of dichloromethane, to the mixture 2.1 ml (0.028 mol) of thionyl chloride and 2 drops of N,N-dimethylformamide as catalyst are added. The suspension is refluxed for 5 hours, then evaporated. The residue is dissolved in 30 ml of acetone and added to the refluxing solution of 2.43 g (0.025 mol) of potassium thiocyanate and 10 ml of acetone and heated under reflux conditions for 30 minutes. The reaction mixture is cooled to 10 °C and ammonia gas is introduced into the mixture for a period of 15 minutes. The precipitated solid material is filtered off, the filtrate solution is poured onto 100 ml of water, the precipitated product is washed with ethanol. Product: 3.78 g pale-yellow crystals of the title compound, mp: 220-
223 °C. 7.) Preparation of N-(aminothioxomethyl)-5,7-dimethyl-l-(4- methoxycarbonylbenzyl)-iH-indole-2-carboxamide
3.59 g (10.7 mmol) of 5,7-dimethyl-l-(4-methoxycarbonylbenzyl)-lH- indole-2-carboxylic acid and 1.26 g (11.2 mmol) ~ 0.8 ml of thionyl chloride are refluxed for 1 hour in 20 ml of dichloromethane, in the presence of 1 drop of N,N- dimethylformamide. The dark solution is then evaporated in vacuum and 10 ml of toluene is distilled through the residue. The acid chloride is refluxed in 10 ml of acetone with 1.05 g (10.7 mmol) of potassium thiocyanate for 30 minutes, then the mixture is cooled from ice-water bath to 0-5°C and 2 ml of 25% ammonium hydroxide is added to it. The thick suspension is diluted with 10 ml of acetone and 10 ml of acetonitrile, stirred at room temperature for 30 minutes, then under stirring 90 ml of water is added to the suspension and stirring is continued for another 30 minutes. The crystals are filtered off in vacuum, washed with water to obtain 3.17 g of butter-coloured crystals of the title compound, mp: 222-224 °C.
8.) Preparation of N-(aminothioxomethyl)-5,7-dimethyl-l-(3- methoxycarbonylbenzyl)-iH-indole-2-carboxamide
1.8 g (5.3 mmol) of 5,7-dimethyl-l -(3 -methoxy carbonylbenzy l)-lH-indole- 2-carboxylic acid and 0.65 g (5.6 mmol) ~ 0.4 ml of thionyl chloride are refluxed for 1 hour in 10 ml of dichloromethane, in the presence of 1 drop of N,N- dimethylformamide. The dark solution is then evaporated in vacuum and 10 ml of toluene is distilled through the residue. The acid chloride is refluxed in 25 ml of acetone with 0.53 g (5.3 mmol) of potassium thiocyanate for 30 minutes, then the mixture is cooled from ice-water bath to 5°C and 1 ml of 25% ammonium hydroxide is added to it. The thick suspension is stirred at room temperature for 60 minutes, diluted with 50 ml of water and stirred for another 30 minutes. The crystals are filtered off in vacuum, washed with water to obtain 1.9 g of butter-coloured crystals of the title compound, mp: 198-199 °C. 9.) Preparation of N-(aminothioxomethyl)-l-(ethoxycarbonylethyl)-7H- indole-2-carboxamide
1.5 g (5.7 mmol) of 2-(hydroxycarbonyl)-lH-indole-l-propionic acid ethyl ester and 0.71 g (6 mmol) ~ 0.45 ml of thionyl chloride are refluxed for 40 minutes in 12 ml of dichloromethane, in the presence of 1 drop of N,N-dimethylformamide. The dark solution is then evaporated in vacuum and 10 ml of toluene is distilled through the residue. The acid chloride is refluxed in 15 ml of acetone with 0.56 g (5.7 mmol) of potassium thiocyanate for 1 hour, then the mixture is cooled from ice-water bath to 0-5°C and 1.25 ml of 25% ammonium hydroxide is added to it. The suspension is stirred at room temperature for 30 minutes, diluted with 15 ml of water and stirred for another 30 minutes. The crystals are filtered off in vacuum, washed with water to obtain 1.16 g of yellow crystals of the title compound, mp: 160-162 °C.
10.) Preparation of the mixture of N-(aminothioxomethyl)-4,5-dimethyl-l-(3- methoxycarbonylbenzyl)- lΗ-indole-2-carboxamide and N-(aminothioxomethyl)- 5,6-dimethyl- 1 -(3 -methoxy carbonylmethyl)- lH-indole-2-carboxamide
From the mixture of 4,5-dimethyl-l-(3-methoxycarbonylbenzyl)-lH-indole- 2-carboxylic acid and 5,6-dimethyl- 1 -(3 -methoxy carbonylmethyl)- lH-indole-2- carboxylic acid according to Example 9. butter-coloured crystals of the title compound mixture are obtained, mp: 193-196°C. Preparation of the compounds of the general formula (III)
11.) Preparation of 2-bromo-l-(2,4-dimethoxyphenyl)-3-cyclohexyl-l- propanone
A) Preparation of 3-cyclohexylpropionyl chloride
23.43 g (0.15 mol) of 3-cyclohexylpropionic acid are dissolved in 150 ml of dichoromethane, to the solution 14.6 ml (0.2 mol) of thionyl chloride and 3 drops of dimethylformamide are added and the mixture is refluxed for 3 hours. The reaction mixture is evaporated to obtain 25.72 g of the title product, which can be used without further purification for the next step. B) Preparation of l-(2,4-dimethoxyphenyl)-3-cyclohexyl-l-propanone
The suspension made of 6.8 g (0.042 mol) of iron(III)chloride and 30 ml of dichloromethane is cooled to 5 °C and to it is added dropwise, and under cooling, the mixture of 5.53g (0.04 mol) of 1,3-dimethoxy-benzene and 7.68g (0.044 mol) of 3-cyclohexylpropionyl chloride. The reaction mixture is stirred at room temperature for 3 hours, then it is poured to 100 ml of ice- water, the resulting emulsion is stirred for 30 minutes, the phases are separated and the organic phase is stirred with 40 ml of IN sodium hydroxide solution for 30 minutes. The organic layer is washed with saturated sodium chloride solution and evaporated. The residue is crystallised from the 10/1 mixture of petroleum ether / methanol to obtain 8.0 g white crystals of the title compound, mp: 34-35 °C.
C) Preparation of 2-Bromo-l-(2,4-dimethoxyphenyl)-3-cyclohexyl-l- propanone
To the solution of 2.62 g (9.48 mmol) of l-(2,4-dimethoxyphenyl)-3- cyclohexyl-1-propanone in 10 ml of dichoromethane is dropped at room temperature the solution of 1.6 g (10 mmol) of bromine in 5 ml of dichoromethane. The reaction mixture is stirred at room temperature for 2 hours, then 15 ml of water is added and stirring is continued for another 30 minutes. The phases are separated, the organic layer is washed with 15 ml of water and evaporated. The residue is taken up in a small amount of ethanol, the precipitated crystals are filtered off in vacuum. 1.54 g white crystals of the title compound are obtained, mp: 83-89°C.
12.) Preparation of 2-bromo-l-(2,5-dimethoxyphenyl)-3-cyclohexyl-l- propanone
The proccess described in Example 11. is followed, starting from 1,4- dimethoxybenzene instead of 1,3-dimethoxybenzene. The product obtained by evaporation is an oil, weight: 9.8 g.
13.) Preparation of 2-bromo-l-(2,5-dimethoxy-4-methylphenyl)-3- cyclohexyl- 1 -propanone
A) Preparation of the 4-cyclohexylbutyryl chloride 25,0 g (0.147 mol) of 4-cyclohexylbutyric acid are dissolved in 50 ml of dichoromethane, to the solution 16 ml (0.22 mol) of thionyl chloride and 3 drops of dimethylformamide are added and the mixture is refluxed for 2 hours. The product obtained by evaporation is used without further purification for the next step.
B) Preparation of l-(2,5-dimethoxy-4-methylphenyl)-4-cyclohexyl-l- butanone
The solution of 4.56 g (0.03 mol) of 2,5-dimethoxytoluene and 6.23 g (0.033 mol) of cyclohexylbutyryl chloride in 30 ml of dichloromethane is cooled to 5 °C and to it is added dropwise 5.69 g (0.03 mol) of titanium(IV) chloride. The reaction mixture is allowed to warm up to room temperature, stirred for another 2 hours, poured onto the mixture of 70 ml of ice-water and 30 ml of cone, hydrochloric acid and stirred for 30 minutes. The phases are separated, the aqueous phase is extracted with 30 ml of dichloromethane, the united organic phase is stirred for 30 minutes with 40 ml of IN sodium hydroxide solution, then with 40 ml of saturated sodium chloride solution, dried and evaporated. The residue is taken up in 15 ml of methanol, the crystals are filtered off in vacuum. Product: 6.65 g white crystals of the title compound, mp: 52-53°C.
C) Preparation of 2-bromo-l-(2,5-dimethoxy-4-methylphenyl)-4-cyclohexyl- 1-butanone
To the solution of 3.04 g (0.01 mol) of l-(2,5-dimethoxy-4-methylphenyl)-4- cyclohexyl-1-butanone in 20 ml of dichoromethane is dropped at room temperature the solution of 1.6 g (10 mmol) of bromine in 5 ml of dichoromethane. The reaction mixture is stirred at room temperature for 2 hours, then with 25 ml of water for 15 minutes. The phases are separated, the organic layer is washed with 15 ml of water and evaporated. The residue is taken up in a small amount of ethanol, the precipitated crystals are filtered off in vacuum. 2.64 g yellow crystals of the title compound are obtained, mp: 75-77°C.
14.) Preparation of 2-bromo-l-(2,5-dimethoxy-4-chlorophenyl)-4- cy clohexyl- 1 -butanone A) Preparation of 4-cyclohexylbutyryl chloride
125 ml (1.625 mol) of dimethylformamide is cooled to -5°C and 201 g (1.31 mol) of phosphoryl chloride is added to it, while keeping the temperature at 0-5 °C. The reaction mixture is allowed to warm up to 15°C and 204.3 g (1.25 mol) of 4- cyclohexylbutyric acid is added. The mixture is stirred at room temperature for 4 hours, then the phases are separated. The upper layer, 220.8 g of thick viscosine solution, is taken into the next step without further purification.
B) Preparation of l-(2,5-dimethoxy-4 chlorophenyl)-4-cyclohexyl-l- butanone
Into 480 ml of dichloromethane at 5 °C 175.6 g (1.05 mol) of iron(III) chloride are added, then at that temperature 172.61 g (1 mol) of 2,5- dimethoxychlorobenzene and the 4-cyclohexybutyryl chloride are added. The reaction mixture is stirred for 4 hours, while keeping the temperature below 35 °C, then it is poured to 1500 ml of ice-water and the phases are separated. The aqueous layer is extracted with dichloromethane, the united organic phase is washed IN sodium hydroxide solution, then with saturated sodium chloride solution and evaporated. The residue is suspended in methanol, the crystalline product is filtered off in vacuum. 289.5 g pale-yellow crystals of the title compound are obtained, mp: 79-80°C
C) 2-Bromo- 1 -(2,5-dimethoxy-4-chlorophenyl)-4-cyclohexyl- 1 -butanone
243.3 g (0.749 mol) of l-(2,5-dimethoxy-4-chlorophenyl)-4-cyclohexyl-l- butanone are dissolved in 980 ml of dichoromethane. Into the pale-yellow solution 119.7 g (0.749 mol) of bromine in 380 ml of dichoromethane are dropped at room temperature, in a period of 40 minutes. The brown, clear reaction mixture is stirred at room temperature for 30 minutes, then 1500 ml of water is added and the mixture is stirred for 30 minutes The separated organic layer is stirred again with 750 ml of water for 30 minutes. The phases are separated, the organic layer is evaporated. The oily residue is taken up in 450 ml of ethanol, the precipitated crystals are filtered off in vacuum. 288.4 g light yellow crystals of the title compound are obtained, mp: 73-
74°C .
15.) Preparation of 2-bromo- 1 -(2,5-dimethoxy-4-chlorophenyl)- 1 -decanone
A) Preparation of 1 -(2, 5 -dimethoxy-4-chlorophenyl)-l -decanone The solution of 8.63 g (0.05 mol) of 2,5-dimethoxychlorobenzene and 10.49 g (0.055 mol) of decanoyl chloride in 50 ml of dichloromethane is cooled to 5 °C and to it is added dropwise 9.48 g (0.05 mol) of titanium(IV) chloride. The reaction mixture is allowed to warm up to room temperature, stirred for another 2 hours, poured onto the mixture of 100 ml of ice-water and 40 ml of cone, hydrochloric acid and stirred for 30 minutes. The phases are separated, the aqueous phase is extracted with 30 ml of dichloromethane, the united organic phase is stirred for 30 minutes with 60 ml of IN sodium hydroxide solution then with 60 ml of saturated sodium chloride solution, dried and evaporated. The residue is taken up in 40 ml of methanol, the crystals are filtered off in vacuum. Product: 12.15 g white crystals, mp: 53-54 °C.
B) Preparation of 2-bromo- 1 -(2,5-dimethoxy-4-chlorophenyl)- 1 -decanone
To the solution of 3.27 g (0.01 mol) of l-(2,5-dimethoxy-4-chlorophenyl)-l- decanone in 20 ml of dichoromethane the solution of 1.6 g (10 mmol) of bromine in 11 ml of dichoromethane is dropped at room temperature. The reaction mixture is stirred at room temperature for 30 minutes, then with 30 ml of water for 30 minutes. The phases are separated, the organic layer is washed with 30 ml of water and evaporated to obtain 3.78 g of the title compound in the form of an oil.
16.) Preparation of 2-bromo-l-(5-bromo-2,5-dimethoxyphenyl)-4- cy clohexyl- 1 -butanone A) Preparation of l-(5-bromo-2,5-dimethoxyphenyι)-4~cy clohexyl- 1- butanone
The solution of 8.68 g (0.04 mol) of l-bromo-2,4-dimethoxybenzene and 7.55 g (0.04 mol) of cyclohexylbutyric acid in 50 ml of dichloromethane is cooled to 0°C and to it is added dropwise 4.4 ml (0.04 mol) of titanium(IV) chloride. The reaction mixture is allowed to warm up to room temperature, stirred for another 5 hours. The reaction mixture is worked-up as described in 13. B) to obtain 10.05 g white crystals of the title compound, mp: 82-87 °C.
B) Preparation of 2-bromo-l-(5-bromo-2,5-dimethoxyphenyl)-4-cyclohexyl- 1-butanone
To the solution of 3.69 g (0.01 mol) of l-(5-bromo-2,5-dimethoxyphenyι)-4- cy clohexyl- 1-butanone in 20 ml of dichoromethane the solution of 1.6 g (10 mmol) of bromine in 15 ml of dichoromethane is dropped at room temperature. The reaction mixture is stirred at room temperature for 30 minutes, then with 50 ml of water for 30 minutes. The phases are separated, the organic layer is washed with 2x30 ml of water and evaporated. The residue is taken up in a small amount of cold ethanol, the precipitated crystals are filtered off in vacuum to obtain 3.09 g white crystals of the title compound, mp: 96-104°C.
17.) Preparation of l-(2,5-dimethoxy-4-chlorophenyl)-2- cy clohexylmethylthio- 1 -ethanone
A) Preparation of cyclohexylmethylthioacetic acid
The mixture of 8.85g (0.05 mol) of cyclohexylmethyl bromide, 100 ml of ethanol and 3.8 g (0.05 mol) of thiocarbamide is heated under reflux conditions for 12 hours, cooled to room temperature, 10 g (0.25 mol) of sodium hydroxide dissolved in 50 ml of water is added and the mixture is refluxed for 2 hours. After cooling to room temperature 7.65 g (0.05 mol) of bromoacetic acid methyl ester in 20 ml of ethanol is added and reflux is continued for 3 hours. Then, under stirring and external cooling the solution of 7ml of cone, sulfuric acid and 80 ml of water is dropped to the reaction mixture (pH=l), the oily product is extracted with 2x150 ml of ethyl acetate, the organic phase is washed with 200 ml of water, dried over sodium sulfate and evaporated. The residual 9.1 g raw product is purified by coloumn chromatography using toluene-methanol 10: 1 mixture eluent. Collecting and evaporating the pure fractions the title compound was obtained in the form of an oil, which was used for the next step without further purification. B) Preparation of cyclohexylmethylthioacetyl chloride
To the solution made of 5.63 g (0.03 mol) of cyclohexylmethylthioacetic acid, and 3.3 ml (0.045 mol) of thionyl chloride in 20 ml of dichoromethane 3 drops of dimethylformamide are added and the mixture is refluxed for 2 hours. The product obtained after evaporation is used without further purification for the next step.
C) Preparation of l-(2,5-dimethoxy-4-chlorophenyl)-2- cyclohexylmethylthio- 1 -ethanone
The solution of 4.70 g (0.027 mol) of 2,5-dimethoxy-4-chlorobenzene and 6.20 g (0.03 mol) of cyclohexylmethylthioacetyl chloride in 30 ml of dichloromethane is cooled to 5°C and to it is added dropwise 2.96 ml (0.027 mol) of titanium(IV) chloride. The reaction mixture is allowed to warm up to room temperature, stirred for another 2 hours, poured onto the mixture of 80 ml of ice- water and 20 ml of cone, hydrochloric acid, stirred for 30 minutes. The phases are separated, the aqueous phase is extracted with 30 ml of dichloromethane, the united organic phase is stirred for 30 minutes with 40 ml of IN sodium hidroxide solution, the organic phase is washed with 40 ml of saturated sodium chloride solution, dried and evaporated. The residue is taken up in 20 ml of methanol. The resulting crystals are filtered off in vacuum, to obtain 5.33 g white crystals of the title compound, mp: 51-53 °C.
D) Preparation of 2-bromo- 1 -(2,5 -dimethoxy-4-chloropheny l)-2- cyclohexylmethy lthio- 1 -ethanone
To 1.85 g (0.0055 mol) of l-(2,5-dimethoxy-4-chlorophenyl)-2- cyclohexy lmethy lthio- 1 -ethanone dissolved in 30 ml of dichloromethane is added at 10°C, in a period of 10 minutes, under stirring the solution of 0.87 g (0.0055 mol) of bromine in 30 ml dichloromethane. The mixture is stirred at room temperature for 15 minutes, washed twice with 40 ml of water and evaporated to obtain 2.1 g of the title compound as a thick oil.
18.) Preparation of l-(2,5-dimethoxy-4-chlorophenyl)-3-cyclohexylthio-l- propanone
A) Preparation of 3-cyclohexylthio-l-propionic acid To the mixture of 11.6 g (0.1 mol) of cyclohexylmercaptan, 70 ml of ethanol and 12 g (0.3 mol) of sodium hydroxide dissolved in 50 ml of water is added at 10- 15 °C, under external heating , the solution of 18.1 g (0.1 mol) of 3-bromopropionic acid ethyl ester in 100 ml of ethanol. The reaction mixture is refluxed for 5 hours, cooled to room temperature and under external heating and stirring the solution of 15 ml of cone, sulfuric acid in 100 ml of water is added to it. The reaction mixture is extracted twice with 200 ml of ethyl acetate. The organic layer is washed with 200 ml of water, dried over anhydrous sodium sulfate and evaporated. The residual 16.5 g of crude product is purified by chromatography using 10: 1 toluene-methanol mixture as eluent. Collecting and evaporating the pure fractions the title compound was obtained in the form of a pale oil, which was used for the next step without further purification.
B) Preparation of 3-cyclohexylthio-l-propionyl chloride
To the solution made of 6.99 g (0.037 mol) of cyclohexylmethylthiopropionic acid, 4.1 ml (0.056 mol) of thionyl chloride and of
30 ml of dichloromethane 3 drops of dimethylformamide are added and the mixture is refluxed for 1 hours. The product obtained after evaporation is used without further purification for the next step.
C) Preparation of l-(2,5-dimethoxy-4-chlorophenyl)-3-cyclohexylthio-l- propanone
The solution of 5.18 g (0.03 mol) of 2,5-dimethoxy-4-chlorobenzene and 6.20 g (0.03 mol) of cyclohexylthiopropionyl chloride in 30 ml of dichloromethane is cooled to 5°C and to it is added dropwise 3.3 ml (0.03 mol) of titanium(IV) chloride. The reaction mixture is stirred at 5-10 °C for 3 hours, then poured onto the mixture of 80 ml of ice-water and 20 ml of cone, hydrochloric acid, stirred for 30 minutes. The phases are separated, the aqueous phase is extracted with 30 ml of dichloromethane, the united organic phase is stirred for 30 minutes with 40 ml of IN sodium hydroxide solution, the organic phase is washed with 40 ml of saturated sodium chloride solution, dried and evaporated. The residue is taken up in 100 ml of petroleum ether to obtain 4.12 g oily product of the title compound. D) Preparation of 2-bromo- l-(2,5~dimethoxy-4-chlorophenyι)-3- cyclohexy lthio- 1 -propanone
To 0.8 g (0.002 mol) of l-(2,5-dimethoxy-4~chlorophenyl)-3-cyclohexylthio- 1 -propanone dissolved in 30 ml of dichloromethane is added at 10°C, in a period of 10 minutes, under stirring the solution of 0.32 g (0.002 mol) of bromine in 20 ml dichloromethane. The mixture is stirred at room temperature for 15 minutes, washed twice with 40 ml of water and evaporated to obtain 0.95 g of the title compound as a thick oil.
Preparation of the compounds of the general formula (I) 19.) Preparation of 2-[[[4-(2,5-dimethoxy-4-chlorophenyl)-5- cyclohexylethylthiazol-2-yl]-amino]-carbonyl]-5,7-dimethyl-lH-indole-l-acetic acid methyl ester
To 880 ml of N,N-dimethylformamide at room temperature, under stirring are added 195.72 g (0.613 mol) of N-(aminothioxomethyl)-5,7-dimethyl-l- (methoxycarbonylmethyl)-lH-indole-2-carboxamide and 247.42 g (0.613 mol) of 2- bromo- 1 -(2,5-dimethoxy-4-chlorophenyl)-4-cyclohexyl- 1 -butanone. The suspension under stirring turnes at 83 °C into a dark solution which is stirred at 95- 105 °C inner temperature for 3,5 hours. The solution is then cooled to 80 °C, 85 ml (62 g = 0.613 mol) of triethylamine is added to it, stirred for 5 minutes and 2640 ml of ethanol is added to it. The pale solution cooles to 45-55 °C and crystallisation starts. The reaction mixture is cooled to room temperature under stirring. The crystals are filtered off in vacuum, washed with ethanol to obtain 315.91 g white cystals of the crude product, mp.: 193-195 °C.
20.) Preparation of 2-[[[4-(2,5-dimethoxyphenyl)-5- cyclohexylmethylthiazol-2-yl]-amino]-carbonyl]-5,7-dimethyl- lH-indole- 1 -acetic acid methyl ester
To 15 ml of N,N-dimethylformamide at room temperature under stirring are added 1.6 g (5 mmol) of N-(aminothioxomethyl)-5,7-dimethyl-l-
(methoxycarbonylmethyl)-lH-indole-2-carboxamide and 2.22 g (6.26 mmol) of 2- bromo-l-(2,5-dimethoxyphenyl)-3-cyclohexyl-l-propanone . The pale-brown solution is stirred for 3 hours at 105 °C inner temperature, cooled to 80 °C, diluted with 90 ml of 50% ethanol and cooled to room temperature under stirring. The resulting crystals are filtered off in vacuum, washed with 50% aqueous ethanol to obtain 2.1 g yellow crystals of the crude product, mp: 89-92 °C.
21.) Preparation of 2-[[[4-(2,5-dimethoxy-4-methylphenyl)-5- cyclohexylethylthiazol-2-yl]-amino]-carbonyl]-5,7-dimethyl- IH-indole- 1 -acetic acid methyl ester
To 15 ml of N,N-dimethylformamide at room temperature under stirring are added 1.6 g (5 mmol) of N-(aminothioxomethyl)-5,7-dimethyl-l- (methoxycarbonylmethyl)-lH-indole-2-carboxamide and 1.97 g (5.2 mol) of 2- bromo-l-(2,5-dimethoxy-4-methylphenyl)-4-cyclohexyl-l-butanone. The suspension turnes at 80 °C under stirring into an orange-coloured solution which is stirred at 100-105 °C inner temperature for 3 hours. The reaction mixture is cooled under stirring to room temperature and poured onto 45 ml of water. The butter- coloured suspension is stirred at room temperature for 30 minutes, the crystals are filtered off in vacuum, crystallized from N,N-dimethylformamide - water mixture. 2.82 g pale beige-coloured crystals are obtained as crude product, mp: 154-162 °C.
22.) Preparation of 2-[[[4-(2,5-dimethoxy-4-methylphenyl)-5- cyclohexylethylthiazol-2-yl]amino]carbonyl]-5-methoxy- IH-indole- 1 -acetic acid methyl ester To 10 ml of N,N-dimethylformamide at room temperature under stirring are added
1 g (3.1 mmol) of N-(aminothioxomethyl)-5 -methoxy- 1 -(methoxy carbonylmethyl)- lH-indole-2-carboxamide and 1.19 g (3.1 mol) of 2-bromo- 1 -(2,5-dimethoxy-4- methylphenyl)-4-cy clohexyl- 1-butanone. The orange-coloured solution is stirred at 100-105 °C inner temperature for 4 hours, cooled to 80 °C under stirring, 0.45 ml of triethylamine is added to it, stirred for 5 minutes, diluted with 40 ml of 96% ethanol. After a few minutes crystallisation starts from the clear brown solution. The suspension is stirred for 30 minutes. Crystals are filtered off in vacuum, washed with 96% ethanol to obtain 1.28 g white crystals of the product, mp: 173-175 °C. 23.) Preparation of 4- [ [2- [ [ [4-(2,5-dimethoxy-4-chlorophenyl)-5- cyclohexylethylthiazol-2-yl] amino] carbonyl] -5,7-dimethyl-lH-indole-l-yl] - methyl] benzoic acid methyl ester
To 15 ml of N,N-dimethylformamide at room temperature under stirring are added 3.0 g (7.6 mmol) of N-(aminothioxomemyl)-5,7-dimethyl~l-(4- methoxycarbonylbenzyl)-lH-indole-2-carboxamide and 3.07 g (7.6 mmol) 2- bromo-l-(2,5-dimethoxy-4-chlorophenyl)-4-cyclohexyl-l-butanone. The suspension turnes at 72 °C under stirring into a brown solution which is stirred at 100-105 °C inner temperature for 3.5 hours. To the reaction mixture cooled to 65 C 1.1 ml (0.77 g=7.6 mmol) of triethylamine is added, stirred for 5 minutes, cooled to room temperature and poured onto the ice-cold mixture of 45 ml of ethanol and 25 ml of water. The butter-coloured suspension is stirred at room temperature for 60 minutes, the crystals are filtered off in vacuum, washed with water to obtain 4.9 g pale-beige coloured crystals of the title compound, mp: 199-200 °C. 24.) Preparation of 3- [ [2- [ [ [4-(2,5-dimethoxy-4-chlorophenyl)-5- octylthiazol-2-yl] amino] carbonyl] -5,7-dimethyl- IH-indole- 1-yl] methyl] benzoic acid methy ester
To 10 ml of N,N-dimethylformamide at room temperature under stirring are added 1.78 g (4.5 mmol) of N-(aminothioxomethyl)-5,7-dimethyl-l-(3- methoxycarbonylbenzyl)-lH-indole-2-carboxamide and 1.83 g (4.5 mmol) of 2- bromo-l-(2,5-dimethoxy-4-chlorophenyl)-l-decanone. The suspension turnes at 38 °C under stirring into a brown solution which is stirred at 100-105 °C inner temperature for 4 hours. To the reaction mixture cooled to 80 °C 0.6 ml (0.44g=4.5 mmol) of triethylamine is added, stirred for 5 minutes, cooled to room temperature and poured onto 30 ml of ethanol. The butter-coloured suspension is stirred at room temperature for 60 minutes, then from ice- water bath for 30 minutes. The crystals are filtered off in vacuum, washed with ethanol to obtain 2.61 g pale-beige coloured crystals of the title compound, mp: 195-197 °C. 25.) Preparation of 2-[[[4-(2,5-dimethoxy-4-chlorophenyl)-5- cyclohexylethyl-thiazol-2-yl]amino]carbonyl]-5-methyl-lH-indole-l-acetic acid methyl ester
To 18 ml of N,N-dimethylformamide at room temperature under stirring are added 3.56 g (11.7 mmol) of N-(aminothioxomethyl)-5-methyl-l-
(methoxy carbonylmethyl)- lH-indole-2-carboxamide and 4.75 g (11.7 mol) of 2- bromo- 1 -(2, 5 -dimethoxy-4-chloropheny l)-4-cy clohexyl- 1 -butanone. The suspension turnes at 82 °C under stirring into a dark solution which is stirred at 100-105 °C inner temperature for 5.5 hours. To the reaction mixture 30 ml of ethanol is added, at 38-40 °C the crystallization starts. The reaction mixture is cooled under stirring to room temperature and stirred for 30 minutes. The crystals are filtered off in vacuum, washed with ethanol to obtain 5.85 g white crystals of the title compound, mp: 170-171 °C.
26.) Preparation of 2-[[[4-(2,5-dimethoxyphenyl)-5- cyclohexylmethylthiazol-2-yl]amino]carbonyl]-5,7-dimethyl- lH-indolee
N-(aminothioxomethyl)-5,7-dimethyl- lH-indole-2-carboxamide and 2- bromo-l-(2,5-dimethoxyphenyl)-2-cyclohexyl-l-ethanone are reacted according to
Example 25. The crude product is purified by chomatography using toluene- methanol 10:1 mixture eluent to obtain the title compound as white crystals, mp: 203-205 °C.
27.) Preparation of 2-[[[4-(2,5-dimethoxy-4-chlorophenyl)-5- cyclohexylethyl-thiazol-2-yl]amino]carbonyl]-3 ,5-dimethyl- IH-indole- 1 -acetic acid methyl ester
N-(aminothioxomethyl)-3 , 5 -dimethyl- 1 -(methoxycarbony lmethy 1)- 1H- indole-2-carboxamide and 2-bromo- 1 -(2,5-dimethoxy-4-chloropheny l)-4- cy clohexyl- 1-butanone are reacted according to Example 25. White crystals of the title compound are obtained, mp: 166-168 °C.
28.) Preparation of the mixture of 2-[[[4-(2,5-dimethoxy-4-chlorophenyl)-5- cyclohexylethylthiazol -2-yl]amino]carbonyl]-4,5-dimethyl- IH-indole- 1 -acetic acid methyl ester and 2-[[[4-(2,5-dimethoxy-4-chlorophenyl)-5-cyclohexylethylthiazol- 2-yl]amino]carbonyl]-5,6- dimethyl- IH-indole- 1 -acetic acid methyl ester The mixture of N-(aminothioxomethyl)-4,5-dimethyl-l-
(methoxycarbonylmethyl)-7H-indole-2-carboxamide and N-(aminothioxomethyl)- 5,6-dimethyl- 1 -(methoxycarbonyl-methyl)- /H-indole-2-carboxamide is reacted with 2-bromo- 1 -(2,5-dimethoxy-4-chloro-phenyl)-4-cy clohexyl- 1 -buthanone according to Example 25. White crystals of the title compound are obtained, mp: 147-148°C.
29.) Preparation of 2-[[[4-(2,5-dimethoxy-4-chlorophenyl)-5- cyclohexylethyl-thiazol-2-yl]amino]carbonyl]- IH-indole- 1 -propionic acid ethyl ester N-(aminothioxomethyl)- 1 -(ethoxycarbonyl ethyl)- lH-indole-2-carboxamide and 2-bromo- 1 -(2,5-dimethoxy-4-chlorophenyl)-4-cy clohexyl- 1 -butanone are reacted according to Example 25. Butter-coloured crystals of the title compound are obtained, mp: 79-85 °C.
30.) Preparation of 2-[[[4-(2,5-dimethoxy-4-chlorophenyl)-5-octylthiazol-2- yl] amino]carbonyl]- IH-indole- 1 -propionic acid ethyl ester
N-(aminothioxomethyl)- 1 -(ethoxy carbonylethyl)- lH-indole-2-carboxamide and 2-bromo- l-(2,5-dimethoxy-4-chlorophenyl)-l -decanone are reacted according to Example 25. Yellow-coloured crystals of the title compound are obtained, mp: 59-61 °C. 31.) Preparation of 2-[[[4-(5-bromo-2,4-dimethoxyphenyl)-5- cyclohexylethyl-thiazol-2-yl]amino]carbonyl]- IH-indole- 1 -acetic acid methyl ester
N-(aminothioxomethyl)- 1 -(methoxycarbonylmethyl)-5 ,7-dimethyl- 1H- indole-2-carboxamide and 2-bromo- 1 -(5-bromo-2,4-dimethoxyphenyl)-4- cy clohexyl- 1-butanone are reacted according to Example 25. Yellow crystals of the title compound are obtained, mp: 110-114°C.
32.) Preparation of 3-[[2-[[[4-(2,5-dimethoxy-4-methylphenyl)-5- cyclohexylethyl-thiazol-2-yl]amino]carbonyl]-5,7-dimethyl- IH-indole- 1 - yl]methyl]benzoic acid methyl ester
N-(aminoιhioxomethyl)-5,7-dimethyl-l-(3-methoxycarbonylbenzyl)-lΗ- indole-2-carboxamide and 2-bromo- l-(2,5-dimethoxy-4-methylphenyl)-4- cy clohexyl- 1-butanone are reacted according to Example 25. Yellow crystals of the title compound are obtained, mp: 219-220°C.
33.) Preparation of 3- [ [2- [ [ [4-(5-bromo-2,4-dimethoxyphenyl)-5- cyclohexyl-ethylthiazol-2-yl] -amino] carbonyl] -5,7-dimethyl-lH-indole-l-yl] - methyl] benzoic acid methyl ester
N-(aminothioxomethyl)-5 ,7-dimethyl- 1 -(3 -methoxy carbonylbenzy 1)- 1 H- indole-2-carboxamide and 2-bromo- 1 -(5-bromo-2,4-dimethoxyphenyι)-4- cy clohexyl- 1-butanone are reacted according to Example 25. White crystals of the title compound are obtained, mp: 218-220°C. 34.) Preparation of 3- [ [2- [ [ [4-(2,5-dimethoxy-4-chlorophenyl)-5- octylthiazol-2-yl] amino] carbonyl] -2,5-dimethyl-lH-indole-l-yl] methyl] benzoic acid methyl ester
N-(aminothioxomethyl)-2, 5-dimethyl- 1 -(3 -methoxy carbonylbenzy 1)- 1 H- indole-2-carboxamide and 2-bromo- 1 -(2,5-dimethoxy-4-chlorophenyl)- 1 -decanone are reacted according to Example 25. White crystals of the title compound are obtained, mp: 165-166°C.
35.) Preparation of the mixture of 2-[[[4-(2,5-dimethoxy-4-methylphenyl)-5- cyclohexylethylthiazol -2-yl]amino]carbonyl]-4,5-dimethyl-lH-indole-l-acetic acid methyl ester and 2-[[[4-(2,5-dimethoxy-4-methylphenyl)-5-cyclohexylethylthiazol - 2-yl]amino]carbonyl]-5,6-dimethyl-lH-indole-l-acetic acid methyl ester
The mixture of N-(aminothioxomethyl)-4, 5 -dimethyl- 1-
(methoxycarbonylmethyl)-7H-indole-2-carboxamide and N-(aminothioxomethyl)- 5,6-dimethyl- 1 -(methoxycarbonyl-methyl)-7H-indole-2-carboxamide is reacted with 2-bromo- 1 -(2, 5 -dimethoxy-4-methylhenyl)-4-cy clohexyl- 1 -butanone according to Example 25. White crystals of the title compound are obtained, mp: 112-125°C.
36.) Preparation of 2-[[[4-(2,5-dimethoxy-4-chlorophenyl)-5- cyclohexylmethyl-thiazol-2-yl]amino]carbonyl]-5 ,7-dimethyl- IH-indole- 1 -acetic acid methyl ester The solution of 1.8 g (4 mmol) of l-(2,5-dimethoxy-4-chlorophenyl)-2- bromo-2-cyclohexylmethylthio-l -ethanone and 10 ml N,N-dimethylformamide is added to the suspension of 0.65 g (2 mmol) of N-(aminothioxomethyl)-5,7- dimethyl-l-(methoxycarbonylmethyl)-iH-indole-2-carboxamide and 5 ml of N,N- dimethylformamide and the reaction mixture is stirred at 95 °C for 3 hours. The dark-yellow solution is cooled down and 30 ml of water is added. From the precipitated amorphous material the solvent is decanted, 25 ml of ethanol is added to crystallize the product, which is filtered off and dried at room temperature. 0.9 g yellow crystalline product is obtained, mp: 143-145 °C. 37.) Preparation of 2-[[[4-(2,5-dimethoxy-4-chlorophenyl)-5-cyclohexylthio- methylthiazol-2-yl]amino]carbonyl]-5,7-dimethyl- IH-indole- 1 -acetic acid methyl ester l-(4-chloro-2,5-dimethoxyphenyl)-2-bromo-2-cyclohexylthiomethyl-l- ethanone and N-(aminothioxomethyl)-5,7-dimethyl- 1 -(methoxy carbonylmethyl)- yH-indole-2-carboxamide are reacted in N,N-dimethylformamide as described above. Mp: 130-136 °C.
38.) Preparation of 2-[[[4-(2,5-dimethoxy-4-chlorophenyl)-5-cyclohexyl- ethylthiazol-2-yl]amino]carbonyl]-5,7-dimethyl- IH-indole- 1 -acetic acid
59.28 g (1.482 mol) of sodium hydroxide is dissolved in 3500 ml ethanol and to the solution is added under stirring 308.27 g (0.494 mol) of 2-[[[4-(4- chloro-2,5-dimethoxyphenyl)-5-cyclohexylethylthiazol-2-yl]amino]carbonyl]-5,7- dimethyl- IH-indole- 1 -acetic acid methyl ester. The mixture is stirred for 2 hours at 50-55°C inner temperature, the opaque solution is filtered, then acidified at that temperature with 510 ml (534 g = 8.892 mol) of acetic acid. The thick suspension is cooled to room temperature, the crystals are filtered off in vacuum, thoroughly washed with ethanol. 291.66 g white crystals of the title compound are obtained, mp: 227-228 °C.
39.) Preparation of 2-[[[4-(2,5-dimethoxy-4-chlorophenyl)-5- cyclohexylethyl-thiazol-2-yl]amino]carbonyl]-3 ,5-dimethyl- IH-indole- 1 -acetic acid From 2-[[[4-(2,5-dimethoxy-4-chlorophenyl)-5-cyclohexylethylthiazol-2- yl]amino]carbonyl]-3, 5 -dimethyl- IH-indole- 1 -acetic acid methyl ester according to Example 38., using hydrochloric acid of 10% for acidification, white crystals of the title compound are obtained, mp: 151-160 °C. 40.) Preparation of 2-[[[4-(2,5-dimethoxy-4-chlorophenyl)-5- cyclohexylethylthiazol-2-yl]amino]carbonyl]-5-methyl-lH-indole-l-acetic acid
From 2-[[[4-(2,5-dimethoxy-4-chlorophenyl)-5-cyclohexylethylthiazol-2- yl]amino]carbonyl]- 5 -methyl-lH-indole-1 -acetic acid methyl ester according to Example 38., using 1 : 1 hydrochloric acid solution for acidification, white crystals of the title compound are obtained, mp: 204-208 °C.
41.) Preparation of the mixture of 2-[[[4-(2,5-dimethoxy-4-chlorophenyl)-5- cyclohexylethylthiazol-2-yl]amino]carbonyl]- 4,5-dimethyl and -5,6-dimethyl- IH- indole- 1 -acetic acid
From the mixture of 2-[[[4-(2,5-dimethoxy-4-chlorophenyl)-5- cyclohexylethyl-thiazol-2-yl]amino]carbonyl]- 4,5-dimethyl and -5,6-dimethyl- IH- indole- 1 -acetic acid methyl ester according to Example 38., using hydrochloric acid of 10% for acidification, white crystals of the title compound are obtained, mp: 198- 200 °C.
42.) Preparation of 2-[[[4-(2,5-dimethoxy-4-methylphenyl)~5- cyclohexylethyl-thiazol-2-yl]amino]carbonyl]-3, 5 -dimethyl- IH-indole- 1 -acetic acid
From 2-[[[4-(2,5-dimethoxy-4-methylphenyl)-5-cyclohexylethylthiazol-2- yl]amino]carbonyl]-3,5-dimethyl- IH-indole- 1 -acetic acid methyl ester according to
Example 38., white crystals of the title compound are obtained, mp: 150-152°C.
43.) Preparation of 2-[[[4-(2,5-dimethoxy-4-methylphenyi)-5- cyclohexylethyl-thiazol-2-yl]amino]carbonyl]-5-methoxy- IH-indole- 1 -acetic acid
From 2-[[[4-(2,5-dimethoxy-4-methylphenyl)-5-cyclohexylethylthiazol-2- yl]amino]carbonyl]-5-methoxy- IH-indole- 1 -acetic acid methyl ester according to
Example 38., white crystals of the title compound are obtained, mp: 163-165°C.
44.) Preparation of 2-[[[4-(5-bromo-2,4-dimethoxyphenyl)-5- cyclohexylethyl-thiazol-2-yl]amino]carbonyl]-5,7-dimethyl-lH-indole-l-acetic acid From 2-[[[4-(5-bromo-2,4-dimethoxyphenyl)-5-cyclohexylethylthiazol-2- yl]amino]carbonyl]-5,7-dimethyl- IH-indole- 1 -acetic acid methyl ester according to Example 38., white crystals of the title compound are obtained, mp: 221-222°C.
Fig. 1 shows the general formula (I), Fig. 2 shows the general formula (II), Fig. 3 shows the general formula (III), Fig. 4 shows the general formula (IV), Fig. 5 shows the general formula (V), Fig. 6 shows the general formula (VI), Fig. 7 shows the general formula (VII), Fig. 8 shows the general formula (VIII), Fig. 9 shows the general formula (IX), Fig. 10 shows the general formula (X), Fig. 11 shows the general formula (XI), Fig. 12 shows the general formula (XII), Fig. 13 shows the general formula (XIII), Fig. 14 shows the general formula (XIV), Fig. 15 shows the general formula (XV) and Fig. 16 shows the general formula (XVI).

Claims

What we claim is:
1.) Process for the preparation of a compound of the general formula (I), pharmaceutically acceptable salts and solvates thereof-wherein R1 stands for hydrogen or methyl group,
R2, R3,R4, R5 stand independently from each other for hydrogen, methyl, ethyl, hydroxyl, acetyloxy, methoxy, ethoxy, methyltio, trifluoromethyl or amino group or halogen atom,
R stands for hydrogen, a -(CH2)nR6 group or a group of the general formula a.), wherein
R6 stands for carboxyl or a -COOR7 group,
R7 stands for a Cι_ alkyl group, n= 1, 2, 3, 4 or 5, m= zero or 1, R8 stands for a substituted phenyl group of the general formula b.), wherein
I π
R stands for hydrogen or methoxy group,
R11 stands for hydrogen, methyl, ethyl, isopropyl, methoxy or ethoxy group or halogen atom,
19 R stands for hydrogen, methyl, ethyl or methoxy group or halogen atom, or
I I 19
R and R form together a methylenedioxy group,
R9 stands for a -CH2-R13, -(CH2)2-R13, -S-CH2-R13, -CH2-S-R13 or C5.8 alkyl group, wherein R13 stands for C5.7 cycloalkyl group, with the proviso that R10, R11 and R12 can not stand at the same time for hydrogen-, characterised by reacting an N-(amino-tioxo-methyl)-lH-indole-2-carboxamide of the general formula (II), wherein R1, R2 , R3, R4 , R5 and R are as defined above, with an α-halogen-ketone of the general formula (III), wherein X stands for halogen atom, R8 and R9 are as defined above and transforming the compound of the general formula (I) or its solvate thus obtained into its salt or liberating from its salt.
2.) Process according to claim 1, characterised by carrying out the reaction in the presence of a solvent.
3.) Process according to claims 1 and 2, characterised by using as solvent aprotic solvents, preferably N,N dimethyl-formamide or N-methyl-2-pyrrolidone.
4.) Process according to claim 1, characterised by carrying out the reaction between room temperature and 120 °C, preferably between 80 °C and 120 °C.
5.) Compounds of the general formula (II), wherein
R1 stands for hydrogen or methyl group R2, R3,R4, R5 stand independently from each other for hydrogen, methyl, ethyl, hydroxyl, acetyloxy, methoxy, ethoxy, methyltio, trifluoromethyl or amino group or halogen atom,
R stands for hydrogen, a -(CH2)nR6 group or a group of the general formula a.), wherein R6 stands for carboxyl or a -COOR7 group
R7 stands for a Cι_4 alkyl group n= 1, 2, 3, 4 or 5 m= zero or 1-.
6.) Process for the preparation of a compound of the general formula (II), wherein
R1 stands for hydrogen or methyl group,
R2, R3,R4, R5 stand independently from each other for hydrogen, methyl, ethyl, hydroxyl, acetyloxy, methoxy, ethoxy, methyltio, trifluoromethyl or amino group or halogen atom, R stands for hydrogen, a -(CH2)nR6 group or a group of the general formula a.), wherein
Figure imgf000030_0001
group, R7 stands for a Cι_4 alkyl group, n= 1, 2, 3, 4 or 5, m= zero or 1-, characterised by transforming an lH-indole-2-carboxylic acid of the general formula (V), wherein R1, R2, R3, R4, R5 and R are as defined above, into an 1H- indole-2-carboxylic acid halogenide of the general formula (VI), wherein Hlg stands for halogen and R1, R2, R3, R4, R5 and R are as defined above, reacting the compound of the general formula (VI), thus obtained with potassium- tiocyanate, and reacting the isotiocyanate of the general formula (VIII), thus obtained, wherein R1, R2, R3, R4, R5 and R are as defined above, with ammonia or ammonium-hydroxyde.
7.) Process according to claim 6, characterised by carrying out the reaction of the compound of the general formula (VI) with potassium-tiocyanate in the presence of a diprotic-aprotic solvent, using as solvent preferably acetone or methyl- ethyl-ketone.
8.) Compounds of the general formula (III), wherein R8 stands for a substituted phenyl group of the general formula b.), wherein
R10 stands for hydrogen or methoxy group,
Ru stands for hydrogen, methyl, ethyl, isopropyl, methoxy or ethoxy group or halogen atom,
I 9 R stands for hydrogen, methyl, ethyl or methoxy group or halogen atom, or
I I 1
R and R form together a methylenedioxy group, R9 stands for an -S-CH2-R13, or -CH2-S-R13 group, wherein
R13 stands for C5.7 cycloalkyl group, with the proviso that R10, R11 and R12 can not stand at the same time for hydrogen.
9.) Process for the preparation of a compound of the general formula (III), wherein R8 stands for a substituted phenyl group of the general formula b.), wherein
R10 stands for hydrogen or methoxy group, R11 stands for hydrogen, methyl, ethyl, isopropyl, methoxy or ethoxy group or halogen atom,
I 9
R stands for hydrogen, methyl, ethyl or methoxy group or halogen atom, or
I I 1
R and R form together a methylenedioxy group, R9 stands for an -S-CH2-R13, or -CH2-S-R13 group, wherein
■t o 1 ft 1 1 19
R stands for C5.7 cycloalkyl group, with the proviso that R , R and R can not stand at the same time for hydrogen-, characterised by acylating a methoxy-benzene of the general formula (X), wherein R10, R11, and R12 are as defined above, with an acid-choride of the general formula (XI), wherein R14 stands for a C5.7 cycloalkyl group, o stands for 1 or 2, p stands for zero or 1, in the presence of a Lewis acid, and halogenating the compound of the general formula (IX), wherein R9 stands for - S-CH2-R13 or -CH2-S-R13 in a manner known per se.
10.) Process according to claim 9, characterised by using titanium-tetrachloride or aluminium-chloride as Lewis acid.
PCT/HU2001/000121 2000-11-28 2001-11-27 Chemical process and new intermediates Ceased WO2002044150A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MXPA03004426A MXPA03004426A (en) 2000-11-28 2001-11-27 Chemical process and new intermediates.
EP01998539A EP1345897A1 (en) 2000-11-28 2001-11-27 Chemical process and new intermediates
US10/432,494 US20040198793A1 (en) 2000-11-28 2001-11-27 Chemical process and new intermediates
PL01363702A PL363702A1 (en) 2000-11-28 2001-11-27 Chemical process and new intermediates
BR0115501-6A BR0115501A (en) 2000-11-28 2001-11-27 Chemical process and new intermediates
CA002430064A CA2430064A1 (en) 2000-11-28 2001-11-27 Chemical process and new intermediates
AU2002220932A AU2002220932A1 (en) 2000-11-28 2001-11-27 Chemical process and new intermediates
HU0303062A HUP0303062A2 (en) 2000-11-28 2001-11-27 New process and new intermediates for preparation of carboxamido-thiazole derivatives
JP2002546520A JP2004518641A (en) 2000-11-28 2001-11-27 Chemical methods and new intermediates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP0004741 2000-11-28
HU0004741A HUP0004741A2 (en) 2000-11-28 2000-11-28 Chemical process for the preparation of thiazole derivatives and a new intermediate

Publications (1)

Publication Number Publication Date
WO2002044150A1 true WO2002044150A1 (en) 2002-06-06

Family

ID=89978805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2001/000121 Ceased WO2002044150A1 (en) 2000-11-28 2001-11-27 Chemical process and new intermediates

Country Status (12)

Country Link
US (1) US20040198793A1 (en)
EP (1) EP1345897A1 (en)
JP (1) JP2004518641A (en)
CN (1) CN1478075A (en)
AU (1) AU2002220932A1 (en)
BR (1) BR0115501A (en)
CA (1) CA2430064A1 (en)
CZ (1) CZ20031813A3 (en)
HU (1) HUP0004741A2 (en)
MX (1) MXPA03004426A (en)
PL (1) PL363702A1 (en)
WO (1) WO2002044150A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108671A1 (en) * 2003-06-06 2004-12-16 Suven Life Sciences Limited Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
US7205290B2 (en) 2003-04-01 2007-04-17 Sanofi-Aventis Deutschland Gmbh Diphenylazetidinone with improved physiological properties, process for its preparation, medicaments comprising this compound, and its use
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US8003636B2 (en) 2007-11-13 2011-08-23 Sanofi-Aventis Deutschland Gmbh Certain crystalline diphenylazetidinone hydrates, pharmaceutical compositions thereof and methods for their use
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2020033919A1 (en) 2018-08-10 2020-02-13 Diapin Therapeutics, Llc Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
WO2021174048A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
US11512065B2 (en) 2019-10-07 2022-11-29 Kallyope, Inc. GPR119 agonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0780380A1 (en) * 1995-12-22 1997-06-25 Ss Pharmaceutical Co., Ltd. Triazole derivatives with antimycotic action and intermediates
WO1998051686A1 (en) * 1997-05-13 1998-11-19 Sanofi-Synthelabo N-triazolyl-2-indolecarboxamides and their use as cck-a agonists
WO1999015525A1 (en) * 1997-09-19 1999-04-01 Sanofi-Synthelabo Carboxamidothiazole derivatives, preparation, pharmaceutical compositions containing them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0780380A1 (en) * 1995-12-22 1997-06-25 Ss Pharmaceutical Co., Ltd. Triazole derivatives with antimycotic action and intermediates
WO1998051686A1 (en) * 1997-05-13 1998-11-19 Sanofi-Synthelabo N-triazolyl-2-indolecarboxamides and their use as cck-a agonists
WO1999015525A1 (en) * 1997-09-19 1999-04-01 Sanofi-Synthelabo Carboxamidothiazole derivatives, preparation, pharmaceutical compositions containing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KENTARO HIRAI ET AL: "Synthesis of 2-disubstituted-amino-4-arylthiazol-5-ylalkanoic acids", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 25, no. 9, 1977, pages 2292 - 2299, XP002192713 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205290B2 (en) 2003-04-01 2007-04-17 Sanofi-Aventis Deutschland Gmbh Diphenylazetidinone with improved physiological properties, process for its preparation, medicaments comprising this compound, and its use
US7772429B2 (en) 2003-04-01 2010-08-10 Sanofi-Aventis Deutschland Gmbh Diphenylazetidinone with improved physiological properties, process for its preparation, medicaments comprising this compound, and its use
WO2004108671A1 (en) * 2003-06-06 2004-12-16 Suven Life Sciences Limited Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US8003636B2 (en) 2007-11-13 2011-08-23 Sanofi-Aventis Deutschland Gmbh Certain crystalline diphenylazetidinone hydrates, pharmaceutical compositions thereof and methods for their use
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2020033919A1 (en) 2018-08-10 2020-02-13 Diapin Therapeutics, Llc Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
US11512065B2 (en) 2019-10-07 2022-11-29 Kallyope, Inc. GPR119 agonists
WO2021174048A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
US12264171B2 (en) 2020-02-28 2025-04-01 Kallyope, Inc. GPR40 agonists

Also Published As

Publication number Publication date
BR0115501A (en) 2003-10-21
PL363702A1 (en) 2004-11-29
EP1345897A1 (en) 2003-09-24
CN1478075A (en) 2004-02-25
HUP0004741A2 (en) 2002-12-28
CA2430064A1 (en) 2002-06-06
JP2004518641A (en) 2004-06-24
US20040198793A1 (en) 2004-10-07
MXPA03004426A (en) 2004-05-04
CZ20031813A3 (en) 2003-09-17
HU0004741D0 (en) 2001-02-28
AU2002220932A1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
EP1345897A1 (en) Chemical process and new intermediates
KR890000370B1 (en) Method for preparing thiazolidine derivatives
RU2059627C1 (en) Bicyclic heterocyclic compound and pharmaceutical composition
JPH04243877A (en) Thioxo heterocyclic compound, process for producing same and medicine having said compound and used for treating leucotriene-mediated disease and condition
JPS58131936A (en) Phenylcarboxylic acid derivatives, manufacture and antagonist against slowly anaphylactic substance
JPS6341903B2 (en)
WO1997044306A1 (en) Chalcone derivatives and drugs containing the same
RU2154635C2 (en) Derivatives of 4-aryl-6-aminonicotinic acid and their salts
DK162443B (en) 1,3-DIACYL-2-OXINDOL COMPOUNDS AND 1-ACYL-2-OXINDOL COMPOUNDS FOR USE AS INTERMEDIATES IN THEIR PREPARATION
JPH0853447A (en) Novel 1,3-dihydro-2h-pyrrolo(2,3-b)pyridin-2-one and oxazolo(4,5-b)pyridin-2(3h)-one compound,their production,and drug composition containing them
JPH0747582B2 (en) Quinazoline-3-alkanoic acid derivative and its salt and process for producing the same
JPH05506455A (en) Quinolinyl-benzoheterobicyclic derivatives as leukotriene D↓4 antagonists
DK169104B1 (en) Analogous Process for Preparation of N-Substituted 2-Pyridylindoles or Salts thereof
JPH05221991A (en) Benzenesulfonamide derivative
DE69104481T2 (en) IMIDAZO [4,5-C] PYRIDINE AS A PAF ANTAGONIST.
EP0190298B1 (en) 4-(isoxazolyl)-thiazole-2-oxamic acids and derivatives thereof
JPS61197577A (en) 1-substituted-6-fluoro-7-(pyrrol-1-yl)-1,4-dihydro-4- oxoquinoline-3-carboxylic acid derivatives and manufacture
CS214806B2 (en) Method of making the derivatives of the auron
JPH06135961A (en) New diphynelpyrrolylfuran derivative
AU665590B2 (en) Heterocyclic compound and cardiotonic containing the same as active ingredient
Labaudiniere et al. . omega.-[(4-Phenyl-2-quinolyl) oxy] alkanoic acid derivatives: a new family of potent LTB4 antagonists
JPS6251672A (en) Novel 2-(4-phenyl-1-piperazinyl alkyl)-aminopyrimidine derivative and acid addition salt thereof
HU196758B (en) Process for production of 3-hidroxi-methil-quinolines and medical compositions containing them
JPH0710863B2 (en) Novel derivative of 4-OH quinolinecarboxylic acid substituted at position 2 with an etherifiable or esterifiable dihydroxy group, a process for its preparation and its use as a medicament
CN101735222B (en) Pyrroloazepine compounds and their use as protein tyrosine phosphatase 1B inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 519/MUMNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/004426

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 6272003

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 2002546520

Country of ref document: JP

Ref document number: 2430064

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 018197116

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: P20030492A

Country of ref document: HR

Ref document number: 2001998539

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV2003-1813

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: PV2003-1813

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2001998539

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10432494

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: PV2003-1813

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001998539

Country of ref document: EP